Andreas Charidimou1, Gregoire Boulouis2, Steven M Greenberg2, Anand Viswanathan2. 1. From the Hemorrhagic Stroke Research Program (A.C., G.B., S.M.G., A.V.), Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; and Department of Neuroradiology (G.B.), Centre Hospitalier Sainte-Anne, Université Paris-Descartes, France. andreas.charidimou.09@ucl.ac.uk. 2. From the Hemorrhagic Stroke Research Program (A.C., G.B., S.M.G., A.V.), Department of Neurology, Massachusetts General Hospital Stroke Research Center, Harvard Medical School, Boston; and Department of Neuroradiology (G.B.), Centre Hospitalier Sainte-Anne, Université Paris-Descartes, France.
Abstract
OBJECTIVE: To assess the association of cortical superficial siderosis (cSS) presence and extent with future bleeding risk in cerebral amyloid angiopathy (CAA). METHODS: This was a meta-analysis of clinical cohorts of symptomatic patients with CAA who had T2*-MRI at baseline and clinical follow-up for future intracerebral hemorrhage (ICH). We pooled data in a 2-stage meta-analysis using random effects models. Covariate-adjusted hazard ratios (adjHR) from multivariable Cox proportional hazard models were used. RESULTS: We included data from 6 eligible studies (n = 1,239). cSS pooled prevalence was 34% (95% confidence interval [CI] 26%-41%; I 2 87.94%; p < 0.001): focal cSS prevalence was 14% (95% CI 12%-16%; I 2 6.75%; p = 0.37), and disseminated cSS prevalence was 20% (95% CI 13%-26%; I 2 90.39%; p < 0.001). During a mean follow-up of 3.1 years (range 1-4 years), 162/1,239 patients experienced a symptomatic ICH-pooled incidence rate 6.9% per year (95% CI 3.9%-9.8% per year; I 2 83%; p < 0.001). ICH incidence rates per year according to cSS status were 3.9% (95% CI 1.7%-6.1%; I 2 70%; p = 0.018) for patients without cSS, 11.1% (95% CI 7%-15.2%; I 2 56.8%; p = 0.074) for cSS presence, 9.1% (95% CI 5.5%-12.8%; I 2 0%; p = 0.994) for focal cSS, and 12.5% (95% CI 5.3%-19.7%; I 2 73.2%; p = 0.011) for disseminated cSS. In adjusted pooled analysis, any cSS presence was independently associated with increased future ICH risk (adjHR 2.14; 95% CI 1.19-3.85; p < 0.0001). Focal cSS was linked with ICH risk (adjHR 2.11; 95% CI 1.31-2.41; p = 0.002), while disseminated cSS conferred the strongest bleeding risk (adjHR 4.28; 95% CI 2.91-6.30; p < 0.0001). CONCLUSION: In patients with CAA, cSS presence and extent are the most important MRI prognostic risk factors for future ICH, likely useful in treatment planning. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in symptomatic CAA survivors with baseline T2*-MRI, cSS (particularly if disseminated, i.e., affecting >3 sulci) increases the risk of future ICH.
OBJECTIVE: To assess the association of cortical superficial siderosis (cSS) presence and extent with future bleeding risk in cerebral amyloid angiopathy (CAA). METHODS: This was a meta-analysis of clinical cohorts of symptomatic patients with CAA who had T2*-MRI at baseline and clinical follow-up for future intracerebral hemorrhage (ICH). We pooled data in a 2-stage meta-analysis using random effects models. Covariate-adjusted hazard ratios (adjHR) from multivariable Cox proportional hazard models were used. RESULTS: We included data from 6 eligible studies (n = 1,239). cSS pooled prevalence was 34% (95% confidence interval [CI] 26%-41%; I 2 87.94%; p < 0.001): focal cSS prevalence was 14% (95% CI 12%-16%; I 2 6.75%; p = 0.37), and disseminated cSS prevalence was 20% (95% CI 13%-26%; I 2 90.39%; p < 0.001). During a mean follow-up of 3.1 years (range 1-4 years), 162/1,239 patients experienced a symptomatic ICH-pooled incidence rate 6.9% per year (95% CI 3.9%-9.8% per year; I 2 83%; p < 0.001). ICH incidence rates per year according to cSS status were 3.9% (95% CI 1.7%-6.1%; I 2 70%; p = 0.018) for patients without cSS, 11.1% (95% CI 7%-15.2%; I 2 56.8%; p = 0.074) for cSS presence, 9.1% (95% CI 5.5%-12.8%; I 2 0%; p = 0.994) for focal cSS, and 12.5% (95% CI 5.3%-19.7%; I 2 73.2%; p = 0.011) for disseminated cSS. In adjusted pooled analysis, any cSS presence was independently associated with increased future ICH risk (adjHR 2.14; 95% CI 1.19-3.85; p < 0.0001). Focal cSS was linked with ICH risk (adjHR 2.11; 95% CI 1.31-2.41; p = 0.002), while disseminated cSS conferred the strongest bleeding risk (adjHR 4.28; 95% CI 2.91-6.30; p < 0.0001). CONCLUSION: In patients with CAA, cSS presence and extent are the most important MRI prognostic risk factors for future ICH, likely useful in treatment planning. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in symptomatic CAA survivors with baseline T2*-MRI, cSS (particularly if disseminated, i.e., affecting >3 sulci) increases the risk of future ICH.
Authors: Sergi Martinez-Ramirez; Jose-Rafael Romero; Ashkan Shoamanesh; Ann C McKee; Ellis Van Etten; Octavio Pontes-Neto; Eric A Macklin; Alison Ayres; Eitan Auriel; Jayandra J Himali; Alexa S Beiser; Charles DeCarli; Thor D Stein; Victor E Alvarez; Matthew P Frosch; Jonathan Rosand; Steven M Greenberg; M Edip Gurol; Sudha Seshadri; Anand Viswanathan Journal: Alzheimers Dement Date: 2015-06-13 Impact factor: 21.566
Authors: Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Han Kyu Na; Jae-Hyun Park; Jung-Hyun Kim; Hee Jin Kim; Sung Tae Kim; David J Werring; Sang Won Seo; Duk L Na Journal: Neurology Date: 2015-01-28 Impact factor: 9.910
Authors: Duangnapa Roongpiboonsopit; Andreas Charidimou; Christopher M William; Arne Lauer; Guido J Falcone; Sergi Martinez-Ramirez; Alessandro Biffi; Alison Ayres; Anastasia Vashkevich; Oluwole O Awosika; Jonathan Rosand; M Edip Gurol; Scott B Silverman; Steven M Greenberg; Anand Viswanathan Journal: Neurology Date: 2016-09-30 Impact factor: 9.910
Authors: Andreas Charidimou; Gregoire Boulouis; Duangnapa Roongpiboonsopit; Eitan Auriel; Marco Pasi; Kellen Haley; Ellis S van Etten; Sergi Martinez-Ramirez; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Joshua N Goldstein; Jonathan Rosand; Anand Viswanathan; Steven M Greenberg; M Edip Gurol Journal: Neurology Date: 2017-10-25 Impact factor: 11.800
Authors: Ashley A Scherlek; Mariel G Kozberg; James A R Nicoll; Valentina Perosa; Whitney M Freeze; Louise van der Weerd; Brian J Bacskai; Steven M Greenberg; Matthew P Frosch; Delphine Boche; Susanne J van Veluw Journal: Brain Commun Date: 2022-02-03
Authors: Lara C Wadi; Mher Mahoney Grigoryan; Ronald C Kim; Chuo Fang; Jeffrey Kim; María M Corrada; Annlia Paganini-Hill; Mark J Fisher Journal: J Neuropathol Exp Neurol Date: 2020-10-01 Impact factor: 3.685
Authors: Laura Gatti; Francesca Tinelli; Emma Scelzo; Francesco Arioli; Giuseppe Di Fede; Laura Obici; Leonardo Pantoni; Giorgio Giaccone; Paola Caroppo; Eugenio Agostino Parati; Anna Bersano Journal: Int J Mol Sci Date: 2020-05-13 Impact factor: 5.923
Authors: Peter B Sporns; Marios-Nikos Psychogios; Grégoire Boulouis; Andreas Charidimou; Qi Li; Enrico Fainardi; Dar Dowlatshahi; Joshua N Goldstein; Andrea Morotti Journal: J Clin Med Date: 2021-03-05 Impact factor: 4.241